BELGRADE, SERBIA–(Marketwire – July 22, 2010) – Hard to Treat Diseases, Inc. (PINK SHEETS:HTDS) http://www.htdsmedical.com) is pleased to announce that researchers from its Slavica BioChem (www.slavicabiochem.com) division established the cooperation with world-leading market analysis company from UK.
Dr. Sanja Pekovic, Chief Project Scientist of HTDS, said, “The Datamonitor Group (http://www.datamonitor.com/) is world leader in the business intelligence sector. We expect that the multiple sclerosis and traumatic brain injury pipeline and unmet analysis needs of these two markets, prepared by Datamonitor’s healthcare and pharmaceutical analysis team, will provide us with insight into most recent findings in order to be a step ahead to our competitors. After getting permission, complete material comprising of clinical opinion, leader intelligence, best-in-class case studies, R&D pipeline, unmet need analysis, scenario-based revenue, epidemiology forecasting, a slide pack and a data pack covering seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) will be available at the HTDS (http://www.htdsmedical.com) and Slavica BioChem (www.slavicabiochem.com) web sites.
About Mina Mar Group:
Mina Mar Group (MMG) is a corporate consultancy firm that specializes in small cap or OTC market business services, including public markets in Frankfurt, Germany, and the UK. We provide our clients with comprehensive advisory and consulting services regarding mergers and acquisitions, including reverse mergers of private companies into publicly traded entities, and special purpose companies (SPC) offshore. MMG also offers a full suite of related ancillary services subsequent to the successful completion of a reverse merger, including private placements, Pink Sheets Adequate Disclosure documentation, various SEC regulatory filings and a broad range of other corporate governance matters. Mina Mar Marketing Group, MMMG (www.minamargroup.net), offers publicly traded companies full array of services such as Investor Relations and maintenance investor awareness. Mina Mar Group pioneered the “Go Public Free” program, the first firm to challenge the short sellers, stock bashers and repeal of the “Communication Decency Act”. Visit www.minamargroup.com/ice to learn more.
Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company’s email database for press releases, “Friday Tips” industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe for opt in mailer at http://www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision’s under the Private Securities Litigation Reform Act of 1995. The words or phrases “can be,” “expects,” “may affect,” “believed,” “estimate,” “project,” and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.’s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.’s control. In addition to those discussed in Hard to Treat Diseases, Inc.’s press releases, public filings, and statements by Hard to Treat Diseases, Inc.’s management, including, but not limited to, Hard to Treat Diseases, Inc.’s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.’s ability to raise additional capital to fund future operations, HTDS Corporation’s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.’s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.